ozempic novo nordisk news

Compounded Ozempic tied to deaths, hospitalizations

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns

the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access ...

Medical Xpress · 3d

Novo Nordisk CEO warns of deaths linked to compounded semaglutide

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.

Becker's Hospital Review · 3d

Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO

Novo Nordisk's CEO told CNN he is "alarmed" by the risks compounded versions of semaglutide — the active ingredient in the company's diabetes drug Ozempic and weight loss drug Wegovy — are posing to users.

6don MSN

Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

11don MSN

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says

It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

6don MSN

Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

STAT11d

Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

FiercePharma4d

After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Investopedia on MSN4d

Novo Nordisk Stock Slips as Sales Grow Less Than Expected

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

6don MSN

With Novo Nordisk success, is there a "Nokia risk" for Denmark?

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

10h

Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Yahoo1d

A stronger Ozempic, a Boeing supplier in trouble, and a simpler Starbucks: Business news roundup

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results